Management of AF events
| . | All AF (n = 76) . | Incident AF (n = 63) . | Recurrent AF (n = 13) . | P . |
|---|---|---|---|---|
| AF Common Terminology Criteria for Adverse Events v4.03 grade, n (%) | ||||
| 1 | 6 (7.9) | 4 (6.3) | 2 (15.4) | .43 |
| 2 | 65 (85.5) | 54 (85.7) | 11 (84.6) | |
| 3 | 5 (6.6) | 5 (7.9) | 0 | |
| 4-5 | 0 | 0 | 0 | |
| AF management, n (%) | ||||
| None | 7 (9.2) | 5 (7.9) | 2 (15.4) | .34 |
| Yes | 69 (90.8) | 58 (92.1) | 11 (84.6) | |
| Rate control | 60 (78.9) | 50 (79.4) | 10 (76.9) | .99 |
| Class II agents* | 43 (56.6) | 35 (55.6) | 8 (61.5) | .77 |
| Class IV agents† | 33 (43.4) | 28 (44.4) | 5 (38.5) | .77 |
| Class V agents‡ | 5 (6.6) | 5 (7.9) | 0 | .58 |
| Rhythm control | 16 (21.1) | 14 (22.2) | 2 (15.4) | .72 |
| Class I agents§ | 8 (10.5) | 7 (11.1) | 1 (7.7) | .99 |
| Class III agents‖ | 11 (14.5) | 10 (15.9) | 1(7.7) | .68 |
| Cardiac ablation | 3 (3.9) | 3 (4.8) | 0 | .99 |
| Cardioversion | 11 (14.5) | 10 (15.9) | 1 (7.7) | .68 |
| Pacemaker¶ | 3 (3.9) | 3 (4.8) | 0 | .99 |
| AF management, n (%) | ||||
| Medical rate control alone | 47 (61.8) | 39 (61.9) | 8 (61.5) | .91 |
| Medical rhythm control alone | 4 (5.3) | 4 (6.3) | 0 | |
| Medical rate and rhythm control combined | 12 (15.8) | 10 (15.9) | 2 (15.4) | |
| Others# | 13 (17.1) | 10 (15.9) | 3 (23.1) | |
| Anticoagulation, n (%) | ||||
| No | 54 (71.1) | 42 (66.7) | 12 (92.3) | .09 |
| Yes | 22 (28.9) | 21 (33.3) | 1 (7.7) | |
| Specific anticoagulant use, n (%) | ||||
| Enoxaparin | 5 (22.7) | 5 (23.8) | 0 | .58 |
| Rivaroxaban | 6 (27.3) | 6 (28.6) | 0 | .58 |
| Apixaban | 3 (13.6) | 2 (9.5) | 1 (7.7) | .44 |
| Dabigatran | 2 (9.1) | 2 (9.5) | 0 | .99 |
| Warfarin | 4 (18.2) | 4 (19) | 0 | .99 |
| Heparin | 3 (13.6) | 3 (14.3) | 0 | .99 |
| Antiplatelet therapy, n (%) | ||||
| No | 36 (47.4) | 33 (52.4) | 3 (23.1) | .07 |
| Yes | 40 (52.6) | 30 (47.6) | 10 (76.9) | |
| Aspirin 81 mg | 11 (27.5) | 8 (26.7) | 3 (30) | .99 |
| Aspirin 162 mg | 1 (2.5) | 1 (3.3) | 0 | |
| Aspirin 325 mg | 28 (70) | 21 (70) | 7 (70) | |
| Ibrutinib status after AF event, n (%) | ||||
| No change | 33 (43.4) | 26 (41.3) | 7 (53.8) | .63 |
| Temporary hold | 35 (46.1) | 29 (46) | 6 (46.2) | |
| Dose reduction | 1 (1.3) | 1 (1.6) | 0 | |
| Discontinued | 7 (9.2) | 7 (11.1) | 0 | |
| . | All AF (n = 76) . | Incident AF (n = 63) . | Recurrent AF (n = 13) . | P . |
|---|---|---|---|---|
| AF Common Terminology Criteria for Adverse Events v4.03 grade, n (%) | ||||
| 1 | 6 (7.9) | 4 (6.3) | 2 (15.4) | .43 |
| 2 | 65 (85.5) | 54 (85.7) | 11 (84.6) | |
| 3 | 5 (6.6) | 5 (7.9) | 0 | |
| 4-5 | 0 | 0 | 0 | |
| AF management, n (%) | ||||
| None | 7 (9.2) | 5 (7.9) | 2 (15.4) | .34 |
| Yes | 69 (90.8) | 58 (92.1) | 11 (84.6) | |
| Rate control | 60 (78.9) | 50 (79.4) | 10 (76.9) | .99 |
| Class II agents* | 43 (56.6) | 35 (55.6) | 8 (61.5) | .77 |
| Class IV agents† | 33 (43.4) | 28 (44.4) | 5 (38.5) | .77 |
| Class V agents‡ | 5 (6.6) | 5 (7.9) | 0 | .58 |
| Rhythm control | 16 (21.1) | 14 (22.2) | 2 (15.4) | .72 |
| Class I agents§ | 8 (10.5) | 7 (11.1) | 1 (7.7) | .99 |
| Class III agents‖ | 11 (14.5) | 10 (15.9) | 1(7.7) | .68 |
| Cardiac ablation | 3 (3.9) | 3 (4.8) | 0 | .99 |
| Cardioversion | 11 (14.5) | 10 (15.9) | 1 (7.7) | .68 |
| Pacemaker¶ | 3 (3.9) | 3 (4.8) | 0 | .99 |
| AF management, n (%) | ||||
| Medical rate control alone | 47 (61.8) | 39 (61.9) | 8 (61.5) | .91 |
| Medical rhythm control alone | 4 (5.3) | 4 (6.3) | 0 | |
| Medical rate and rhythm control combined | 12 (15.8) | 10 (15.9) | 2 (15.4) | |
| Others# | 13 (17.1) | 10 (15.9) | 3 (23.1) | |
| Anticoagulation, n (%) | ||||
| No | 54 (71.1) | 42 (66.7) | 12 (92.3) | .09 |
| Yes | 22 (28.9) | 21 (33.3) | 1 (7.7) | |
| Specific anticoagulant use, n (%) | ||||
| Enoxaparin | 5 (22.7) | 5 (23.8) | 0 | .58 |
| Rivaroxaban | 6 (27.3) | 6 (28.6) | 0 | .58 |
| Apixaban | 3 (13.6) | 2 (9.5) | 1 (7.7) | .44 |
| Dabigatran | 2 (9.1) | 2 (9.5) | 0 | .99 |
| Warfarin | 4 (18.2) | 4 (19) | 0 | .99 |
| Heparin | 3 (13.6) | 3 (14.3) | 0 | .99 |
| Antiplatelet therapy, n (%) | ||||
| No | 36 (47.4) | 33 (52.4) | 3 (23.1) | .07 |
| Yes | 40 (52.6) | 30 (47.6) | 10 (76.9) | |
| Aspirin 81 mg | 11 (27.5) | 8 (26.7) | 3 (30) | .99 |
| Aspirin 162 mg | 1 (2.5) | 1 (3.3) | 0 | |
| Aspirin 325 mg | 28 (70) | 21 (70) | 7 (70) | |
| Ibrutinib status after AF event, n (%) | ||||
| No change | 33 (43.4) | 26 (41.3) | 7 (53.8) | .63 |
| Temporary hold | 35 (46.1) | 29 (46) | 6 (46.2) | |
| Dose reduction | 1 (1.3) | 1 (1.6) | 0 | |
| Discontinued | 7 (9.2) | 7 (11.1) | 0 | |